FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
uniQure N.V. QURE — 8-K: Results of Operations and Financial Condition
neutral
uniQure's BLA for ifezuntirgene inilparvovec has been granted Priority Review with a PDUFA target action date of May 1, 2027, and the company has aligned with the FDA on key elements of the confirmatory study design, with cash and equivalents expected to fund operations into 2030
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →